Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 2/20 | 0.63 |
| ▸ | PRKCG | P05129 | 2/20 | 0.63 |
| ▸ | PRKCB | P05771 | 2/20 | 0.63 |
| ▸ | PRKCA | P17252 | 2/20 | 0.63 |
| ▸ | PRKCH | P24723 | 2/20 | 0.63 |
| ▸ | PRKCI | P41743 | 2/20 | 0.63 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.63 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.63 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.63 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.63 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.63 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | AKT1 | P31749 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8855849 | 0.98 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL8855786 | 0.98 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL8855744 | 0.98 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL253903 | 0.98 | PRKD3 (0.61) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL14560967 | 0.98 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL5447359 | 0.98 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL28598698 | 0.98 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL8855806 | 0.98 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL8855768 | 0.98 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL290985 | 0.98 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141760-A1 | COMPOSITIONS AND METHODS TO INCREASE THE SYSTEMIC BIOAVAILABILITY OF A POLYPEPTIDE THERAPEUTIC AGENT UNDERGOING ORAL ADMINISTRATION | ALGIPHARMA AS (NO) | 2024-07-04 | — | — | WO | claimed |
| CN-117214278-A | In-situ mass spectrum detection method for lipid types and content in goat milk | 陕西科技大学 | 2023-12-12 | — | — | CN | claimed |
| CN-116966167-A | Preparation method of S- (-) -nicotine nano flexible liposome hydrogel patch | 湖北工业大学 | 2023-10-31 | — | — | CN | claimed |
| CN-111500137-B | Antibacterial and antiviral emulsion adhesive film-forming agent, preparation method and application thereof | 刘白玲 | 2022-12-20 | — | — | CN | claimed |
| CN-113166642-A | Polymeric chromophores, compositions comprising the same, and methods of making and using the same | 北卡罗莱纳州立大学 | 2021-07-23 | — | — | CN | claimed |
| WO-2020236600-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | WO | claimed |
| EP-3600380-A1 | ORAL DELIVERY OF PHYSIOLOGICALLY ACTIVE SUBSTANCES | Rezolute, Inc. (US) | 2020-02-05 | — | — | EP | claimed |
| CN-110662550-A | Oral administration of physiologically active substances | 瑞泽路特有限公司 | 2020-01-07 | — | — | CN | claimed |
| US-20180271792-A1 | ORAL DELIVERY OF PHYSIOLOGICALLY ACTIVE SUBSTANCES | REZOLUTE, INC. (US) | 2018-09-27 | — | — | US | claimed |
| WO-2018175250-A1 | ORAL DELIVERY OF PHYSIOLOGICALLY ACTIVE SUBSTANCES | REZOLUTE, INC. (US) | 2018-09-27 | — | — | WO | claimed |
| EP-1427289-B1 | PULSATILE RELEASE COMPOSITIONS AND METHODS FOR ENHANCED GASTROINTESTINAL DRUG ABSORPTION | IONIS PHARMACEUTICALS INC (US) | 2017-05-10 | — | — | EP | claimed |
| CN-103690486-A | Indocyanine green nano-targeted liposome and preparation method and application thereof | SHENZHEN INST OF ADV TECH CAS | 2014-04-02 | — | — | CN | claimed |
| EP-1682151-A1 | ORAL ADMINISTRATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7) EN-2-YL)ALKYL]PHOSPHONIC ACID AND DERIVATIVES | Wyeth (US) | 2006-07-26 | — | — | EP | claimed |
| US-20050142192-A1 | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| WO-2005037287-A1 | ORAL ADMINISTRATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7) EN-2-YL)ALKYL]PHOSPHONIC ACID AND DERIVATIVES | WYETH (US) | 2005-04-28 | — | — | WO | claimed |
| CN-113736782-B | Compositions and methods for inhibiting TMPRSS6 gene expression | 阿尔尼拉姆医药品有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-113057959-B | Ketohexokinase (KHK) iRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-1255306-A | Process for preparing green bio-functional beverage | LI ENHONG (CN) | 2000-06-07 | — | — | CN | disclosed |
| CN-1244792-A | Cleaning articles comprising an inverse emulsion a carrier with absorbing control | PROCTER & GAMBLE (US) | 2000-02-16 | — | — | CN | disclosed |
| CN-1111506-A | Formulations containing carotenoids and procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals | INDENA SPA (IT) | 1995-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050142192-A1 | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives | OPRK1, GRIN2A, GRIN2D | PRKD3 1588/4885PRKCG 1190/4885PRKCB 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.